Status:
COMPLETED
Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients
Lead Sponsor:
Mashhad University of Medical Sciences
Conditions:
Rheumatoid Arthritis
Eligibility:
FEMALE
35-60 years
Phase:
PHASE1
Brief Summary
1. Objectives: Evaluation of mesenchymal stem cell therapy effects on cellular and humoral immune responses in refractory rheumatoid arthritis (RA) patients. 2. Design: This study has been performed a...
Detailed Description
Refractory rheumatoid arthritis patients who met the inclusion/exclusion criteria have been selected. After signing informed consent form, autologous stem cells were obtained by bone marrow aspiration...
Eligibility Criteria
Inclusion
- Resistant RA patients to non-biological DMARDs;
- Treated RA patients by non-biological drugs;
- Treated RA patients by Prednisolone, Hydroxychloroquine, Sulfasalazine and Methotrexate;
- Patients age between 35-60 years;
- Refractory RA patients with no other rheumatologic disorders and inflammatory diseases.
Exclusion
- Non-resistant RA patients to non-biological DMARDs.
Key Trial Info
Start Date :
June 20 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2018
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03333681
Start Date
June 20 2016
End Date
September 15 2018
Last Update
March 13 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.